Yangbing Zhao

Yangbing Zhao is a prominent figure in the field of cancer immunotherapy, with a major interest in T cell based gene and adoptive cell therapies. He has held key positions in various prestigious organizations.

Currently, Yangbing Zhao serves as the President & CSO at UTC Therapeutics Inc. He previously held the role of Director at the T Cell Engineering Lab (TCEL) and Adjunct Associate Professor at the University of Pennsylvania.

Prior to his current role, he was a Research Fellow at the Surgery Branch under NCI/NIH. Additionally, Yangbing Zhao has worked as a Research Associate at Duke University Medical Center and has experience as a Post-Doc and Visiting Scientist at The Weizmann Institute of Science.